This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Culyer Report | |
|---|---|
| Name | Culyer Report |
| Author | Anthony Culyer |
| Country | United Kingdom |
| Subject | Health policy, health economics |
| Published | 2010s |
Culyer Report
The Culyer Report was a landmark UK review of health finance and prioritisation led by Anthony J. Culyer, addressing allocation, equity, and efficiency in public health resource distribution. It examined the roles of institutions such as the National Health Service, the Department of Health and Social Care, and agencies like the National Institute for Health and Care Excellence in setting priorities, drawing on comparative practice from entities including the World Health Organization, the Organisation for Economic Co-operation and Development, and the World Bank. The review interfaced with debates involving policymakers from the Prime Minister of the United Kingdom's office, fiscal authorities such as the HM Treasury, and professional bodies like the Royal College of Physicians and the British Medical Association.
The review was commissioned amid policy discussions triggered by public spending reviews conducted by HM Treasury and strategic health reforms influenced by legislation such as the Health and Social Care Act 2012. Its remit intersected with inquiries and reports from institutions including the King's Fund, the Nuffield Trust, the Health Foundation, and parliamentary committees such as the House of Commons Health and Social Care Committee. The commission drew on precedent reviews and inquiries like the Beveridge Report, the Waterston Commission, and analyses by Jenner Commission-style expert groups, and responded to international comparisons involving the Centers for Medicare & Medicaid Services, the Canadian Institute for Health Information, and the Australian Institute of Health and Welfare.
The report set out findings on distributive principles and operational mechanisms, recommending clearer roles for bodies such as NICE, local commissioners including Clinical Commissioning Groups, and national purchasers linked to NHS England. It advocated for evidence-based prioritisation consistent with frameworks used by the World Health Organization and methodologies employed by the Institute for Health Metrics and Evaluation. Recommendations included strengthening institutional capacity similar to models in the Netherlands Ministry of Health, Welfare and Sport, the Swedish National Board of Health and Welfare, and the Canadian Agency for Drugs and Technologies in Health, enhancing transparency akin to practices at the European Observatory on Health Systems and Policies, and embedding equity safeguards reflecting work by the United Nations Development Programme and the Global Fund.
Methodologically, the review synthesised economic evaluation techniques from health technology assessment literatures linked to NICE guidance, cost-effectiveness work by Michael Drummond, and priority-setting frameworks advanced in publications by the World Bank and the Lancet Commission. It used comparative policy analysis drawing on case studies from the United States Centers for Disease Control and Prevention, the German Federal Joint Committee, and the Japan Ministry of Health, Labour and Welfare. The evidence base incorporated quantitative modelling approaches employed by institutions such as RAND Corporation, qualitative stakeholder mapping consistent with methods used by the Institute for Fiscal Studies, and systematic reviews paralleling standards from the Cochrane Collaboration and the Campbell Collaboration.
Following publication, elements of the report influenced commissioning protocols within NHS England and funding decisions overseen by HM Treasury and the Department of Health and Social Care. Several recommendations informed debates in the House of Lords and implementation discussions involving providers such as NHS Trusts and regulators like the Care Quality Commission. International bodies including the World Health Organization and the OECD cited aspects of the review when advising member states on priority-setting mechanisms, and think tanks like the Institute for Public Policy Research and the Adam Smith Institute referenced its framework in policy papers.
Academic responses ranged from endorsement by health economists associated with universities such as University of York, London School of Economics, and University College London to critiques from clinicians linked to the Royal College of General Practitioners and campaign groups including Doctors for the NHS. Critics argued that recommendations risked technocratic centralisation reminiscent of debates around the Health and Social Care Act 2012 and raised concerns similar to controversies in the NHS reforms of the 1990s and debates involving Rawlsian distributive justice versus utilitarian frameworks advanced by scholars like Amartya Sen and John Rawls. Patient advocacy organisations including Macmillan Cancer Support and Age UK published responses highlighting equity and access implications.
Implementation was partial and iterative, with policy uptake occurring in commissioning rules, assessment processes within NICE, and operational guidance for Clinical Commissioning Groups. Subsequent developments saw cross-references in later reviews and white papers produced by the Department of Health and Social Care and incorporation into international guidance by the World Health Organization and the OECD. The evolving policy landscape, influenced by fiscal events such as periodic Comprehensive Spending Review cycles and public health emergencies like the COVID-19 pandemic, shaped the trajectory of the report's legacy and led to follow-on analyses by organisations such as the Health Foundation and academic centres at Imperial College London and the University of Cambridge.
Category:Health policy reports